背景:头颈部肿瘤的诊断和治疗由于其浸润性和诸如血脑屏障的诊断障碍而面临重大挑战。头部和颈部区域的复杂解剖结构也使肿瘤边界的清晰识别和肿瘤特征的评估复杂化。
目的:本综述旨在探讨分子成像技术在头颈部肿瘤成像中使用靶向造影剂的有效性。头颈部肿瘤成像得益于CT和MRI的综合优势。CT擅长提供快速,高对比度的图像,能够准确定位肿瘤,而MRI提供优越的软组织分辨率,有助于详细评估身体该区域的肿瘤形态。这些新型造影剂中的许多都具有双模态,三模态,甚至双组织靶向成像,扩大了分子成像的视野。用于MRI和CT的新兴造影剂还包括在成像中广泛使用的标准,例如钆和碘基剂,分别,但是有了肽,多肽,或聚合物官能化。与患者的相关性。对于患者来说,这些靶向造影剂的开发和使用具有潜在的重要意义.他们受益于提高肿瘤检测和表征的准确性,这对于有效的治疗计划至关重要。此外,这些药物提供了改善的成像对比度,并具有降低毒性和生物蓄积的额外益处.这篇综述中对临床前纳米颗粒研究的总结为科学家和学生提供了宝贵的资源,这些科学家和学生致力于通过靶向造影剂推进肿瘤诊断和治疗。
BACKGROUND: The diagnosis and treatment of head and neck tumors present significant challenges due to their infiltrative nature and diagnostic hindrances such as the blood-brain barrier. The intricate anatomy of the head and neck region also complicates the clear identification of tumor boundaries and assessment of tumor characteristics.
OBJECTIVE: This review aims to explore the efficacy of molecular imaging techniques that employ targeted
contrast agents in head and neck cancer imaging. Head and neck cancer imaging benefits significantly from the combined advantages of CT and MRI. CT excels in providing swift, high-
contrast images, enabling the accurate localization of tumors, while MRI offers superior soft tissue resolution, contributing to the detailed evaluation of tumor morphology in this region of the body. Many of these novel
contrast agents have integration of dual-modal, triple-modal, or even dual-tissue targeting imaging, which have expanded the horizons of molecular imaging. Emerging contrast agents for the purpose of MRI and CT also include the widely used standards in imaging such as gadolinium and iodine-based agents, respectively, but with peptide, polypeptide, or polymeric functionalizations. Relevance for patients. For patients, the development and use of these targeted
contrast agents have potentially significant implications. They benefit from the enhanced accuracy of tumor detection and characterization, which are critical for effective treatment planning. Additionally, these agents offer improved imaging
contrast with the added benefit of reduced toxicity and bioaccumulation. The summarization of preclinical nanoparticle research in this review serves as a valuable resource for scientists and students working towards advancing tumor diagnosis and treatment with targeted contrast agents.